Indaptus Therapeutics (INDP) reshapes board with two new independents and one exit
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Indaptus Therapeutics announced several board changes. The Board appointed Tim Ruan and Dr. Yi Zhang as independent Class II directors, effective April 22, 2026, with terms expiring at the 2026 annual stockholder meeting. Both bring capital markets, biotechnology, intellectual property, and life sciences expertise.
Each new director will receive an annual cash retainer of $30,000, payable quarterly, plus reimbursement of reasonable expenses, under Independent Director Agreements. They also entered Indemnification Agreements under Delaware law. Tim Ruan joins the Audit Committee and is designated an “audit committee financial expert,” while Dr. Zhang joins the Nominating Committee.
On April 22, 2026, director Matthew McMurdo resigned from the Board, and his resignation was stated not to result from any disagreement regarding operations, policies, or practices. The Board remains classified into three staggered classes, with Class II and Class III terms expiring in 2026 and 2027, respectively.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 5.02, 9.01
2 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Effective date of new directors: April 22, 2026
Annual director cash retainer: $30,000
Board class length: Three-year terms
+4 more
7 metrics
Effective date of new directors
April 22, 2026
Appointment of Tim Ruan and Dr. Yi Zhang as independent directors
Annual director cash retainer
$30,000
Per independent director, payable quarterly under Director Agreements
Board class length
Three-year terms
Board divided into three classes with staggered terms
Class II term end
2026 annual meeting
Term expiration for Class II directors including Ruan and Zhang
Class III term end
2027 annual meeting
Term expiration for Class III directors Junyi Dai and Qinglai Lu
Age of Tim Ruan
40 years
Background detail on newly appointed independent director
Age of Dr. Yi Zhang
48 years
Background detail on newly appointed independent director
Key Terms
independent directors, audit committee financial expert, Indemnification Agreements, Nominating Committee, +1 more
5 terms
independent directors financial
"appointed Mr. Tim Ruan and Dr. Yi Zhang as independent directors of the Board"
Members of a company’s board who do not have significant business, family, or financial ties to the company and are not part of its management; they are chosen to provide impartial oversight of strategy, financial reporting, executive pay and risk. They matter to investors because independent directors act like an objective referee, helping ensure decisions favor shareholders’ long-term interests rather than insiders, which can strengthen trust and reduce the chance of mismanagement or conflicts of interest.
audit committee financial expert financial
"The Board has determined that Mr. Ruan qualifies as an “audit committee financial expert”"
A person on a company’s board who has deep knowledge of accounting, financial reporting and auditing, able to understand and question the books, controls and audit work like a trained mechanic inspecting an engine. Investors care because that expertise helps spot errors, weaknesses or misleading statements early, improving the likelihood that financial reports are accurate and reducing the risk of surprises that can hurt a company’s value.
Indemnification Agreements regulatory
"the Company entered into independent director agreements and indemnification agreements"
Indemnification agreements are contracts in which one party agrees to pay for losses, legal costs, or damages another party might face — like a friend promising to cover repair bills if their dog breaks your window. For investors, these agreements matter because they determine who ultimately bears financial and legal risk, affecting a company’s potential liabilities, cash flow needs, and the willingness of executives or partners to take on roles or deals.
Nominating Committee financial
"Dr. Zhang was appointed to serve as a member of the Nominating Committee of the Board"
A nominating committee is a small group of company directors tasked with finding, evaluating and recommending people to serve on the board. Think of it as a hiring panel that chooses the team responsible for guiding the business and holding management accountable. Investors care because the committee’s choices shape the board’s experience, independence and judgment, which directly affect strategy, oversight, leadership succession and the protection of shareholder interests.
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
What board changes did Indaptus Therapeutics (INDP) disclose in this 8-K?
Indaptus Therapeutics added two independent directors, Tim Ruan and Dr. Yi Zhang, as Class II directors effective April 22, 2026, and reported the resignation of director Matthew McMurdo, which was not due to any disagreement over the company’s operations, policies, or practices.
Who are the new independent directors joining the Indaptus Therapeutics (INDP) board?
The new independent directors are financial executive Tim Ruan and intellectual property and life sciences expert Dr. Yi Zhang. Ruan brings capital markets and biotech finance experience, while Zhang contributes cross-border IP, patent portfolio, and scientific research expertise relevant to life sciences and related industries.
What compensation will the new Indaptus Therapeutics (INDP) directors receive?
Each new independent director will receive an annual cash retainer of $30,000, paid quarterly, plus reimbursement of reasonable out-of-pocket expenses. This compensation is provided under Independent Director Agreements that also outline their service terms and is typical for non-employee board roles in public companies.
Which board committees will the new Indaptus Therapeutics (INDP) directors serve on?
Tim Ruan will serve on the Audit Committee, and the board has determined he qualifies as an “audit committee financial expert.” Dr. Yi Zhang will serve on the Nominating Committee. These assignments align Ruan with financial oversight and Zhang with board nomination and governance matters.
Did the resigning Indaptus Therapeutics (INDP) director report any disagreement with the company?
The filing states that director Matthew McMurdo resigned on April 22, 2026, and that his resignation did not result from any disagreement with the company regarding operations, policies, or practices. This indicates a routine departure rather than one driven by a disclosed governance or policy dispute.
How is the Indaptus Therapeutics (INDP) board structured after these changes?
The board is divided into three classes serving staggered three-year terms. Tim Ruan and Dr. Yi Zhang are appointed as Class II directors with terms expiring at the 2026 annual meeting, while previously appointed directors Junyi Dai and Qinglai Lu serve as Class III directors with terms expiring at the 2027 annual meeting.